Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2007

View Archived Issues

Enzyme inhibitors identified at Schering-Plough with potential in inflammatory disorders

New anticancer agents claimed by several research groups

GlaxoSmithKline reports second quarter 2007 results

Prx2: a novel therapeutic target in Parkinson's disease

Cell Therapeutics to acquire Zevalin from Biogen Idec for U.S. sales and marketing

DelSite begins toxicology studies of GelVac nasal powder H5N1 vaccine

Neopharm provides pipeline update

Positive results for Novo Nordisk's phase III studies of liraglutide

FDA approvable letter issued for Indevus' drug candidate Valstar

Phase III trial reveals phenylalanine reductions with sapropterin

Sinovac prepares to move its H5N1 vaccine into phase II trials

DNA vaccine shows promise in multiple sclerosis

Phenoxodiol may reduce cisplatin-induced neuropathy

Spectrum Pharmaceuticals reports second quarter 2007 results

FDA grants Tikvah Therapeutics' sodium phenylbutyrate orphan drug status

FDA issues approvable letter to Solvay for drug candidate Creon

Intercell reports interim data from phase II trial of HCV vaccine IC-41

Recent Merck patent claims compounds for the treatment of urinary incontinence

Design and pharmacological characterization of ILS-920 presented at ACS meeting

Macrogenics starts phase I trial of West Nile virus neutralizing antibody

Daiichi Sankyo selects DT-831j as clinical candidate for thrombosis

Thymoglobulin to be studied in new onset type 1 diabetes

Lexicon pursues compounds able to reduce peripheral 5-HT levels as an approach to IBS

Novel PPARalpha/gamma agonists improve blood glucose and lipid profiles in animals

Clinical candidate NYP Y5 antagonist discovered at Banyu

BMS designs dual PPARalpha/gamma activators for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...